TIVC NASDAQ
Tivic Health Systems, Inc.
1W: -9.1%
1M: -49.1%
3M: -79.8%
YTD: -80.1%
1Y: -93.2%
3Y: -99.6%
$0.28
-0.00 (-0.04%)
Weekly Expected Move ±17.3%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.3M
52W Range0.255-5.6
Volume137,469
Avg Volume262,634
Beta1.84
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Kevin Handley
Employees52
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-11-11
Websitetivichealth.com
47685 Lakeview Blvd.
Fremont, CA 94538
US
Fremont, CA 94538
US
888 276 6888
About Tivic Health Systems, Inc.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The companyâs pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Latest News
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
Valion Bio Appoints Melinda Lackey as General Counsel
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
12 Health Care Stocks Moving In Friday's Pre-Market Session
Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bolton Sheryle | P-Purchase | 10,000 | $1.04 | 2026-04-15 |
| Valauri Christina Ri | P-Purchase | 19,000 | $0.95 | 2026-04-01 |
| Wolf Lisa G | M-Exempt | 92 | — | 2026-03-18 |
| Wolf Lisa G | M-Exempt | 92 | — | 2026-03-18 |
| Handley Michael K | M-Exempt | 8,824 | — | 2026-02-18 |